 | Up a level |
Le Roux, CW, Lau, DCW, Fujioka, K, Greenway, F, Wilding, JPH 
ORCID: 0000-0003-2839-8404, Jacobsen, PB, Skjoth, T and Madsbad, S
(2017)
Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes.
.
Wilding, JPH ORCID: 0000-0003-2839-8404, Fujioka, K, Greenway, F, Lau, DCW, O'Neil, P, Jacobsen, PB, Skjoth, TV and Madsbad, S
(2016)
Greater weight loss and regression to normoglycaemia, and reduced risk of T2D, at 3 years in early weight loss responders to liraglutide 3.0 mg vs early non-responders.
In: European Association for the Study of Diabetes, 2016-9-11 - 2016-9-15.